Abivax (NASDAQ:ABVX) Shares Down 8.7% - Here's Why

Key Points

• Shares fell 8.7% to about $122 on Monday (intraday low $121.51), with ~494,217 shares traded—roughly 17% below the stock's average daily volume.
• Analyst sentiment is mostly positive: the consensus rating is "Moderate Buy" with an average price target of $128.73, supported by multiple buy/overweight ratings and a few higher targets (e.g., Piper Sandler $142), though one sell rating remains.
• Clinical‑stage fundamentals: Abivax (market cap $9.58B) is developing obefazimod (ABX464) for inflammatory diseases, reported negative EPS of ($2.46) last quarter, and analysts project about -2.83 EPS for the year.

Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) shares were down 8.7% on Monday . The company traded as low as $121.51 and last traded at $122.15. Approximately 494,217 shares were traded during trading, a decline of 17% from the average daily volume of 598,886 shares. The stock had previously closed at $133.77.

Wall Street Analyst Weigh In

ABVX has been the subject of a number of recent analyst reports. Morgan Stanley increased their target price on shares of Abivax from $71.00 to $101.00 and gave the company an "overweight" rating in a research report on Friday, September 12th. Wall Street Zen downgraded shares of Abivax from a "hold" rating to a "sell" rating in a research report on Saturday, December 13th. Piper Sandler reiterated an "overweight" rating and issued a $142.00 price target on shares of Abivax in a report on Tuesday, December 16th. Wolfe Research raised shares of Abivax to a "strong-buy" rating in a research report on Thursday, November 6th. Finally, Citigroup restated an "outperform" rating on shares of Abivax in a research report on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Abivax currently has a consensus rating of "Moderate Buy" and an average price target of $128.73.

Abivax Stock Performance

The firm has a market capitalization of $9.58 billion, a PE ratio of -29.37 and a beta of 0.68. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average of $118.09 and a 200 day moving average of $81.65.

Abivax (NASDAQ:ABVX - Get Free Report) last posted its quarterly earnings data on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The firm had revenue of ($4.92) million for the quarter. Equities research analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Institutional Investors Weigh In On Abivax

Institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its stake in shares of Abivax by 4,612.5% during the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after acquiring an additional 369 shares during the last quarter. First Horizon Corp bought a new stake in Abivax in the third quarter valued at $36,000. Union Bancaire Privee UBP SA bought a new position in Abivax in the fourth quarter worth about $67,000. Hantz Financial Services Inc. purchased a new position in shares of Abivax in the 3rd quarter valued at approximately $52,000. Finally, Gordian Capital Singapore Pte Ltd bought a new stake in shares of Abivax during the 3rd quarter valued at $76,000. Hedge funds and other institutional investors own 47.91% of the company's stock.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.